Nordihydroguaiaretic acid can suppress progression of experimental autoimmune encephalomyelitis
- 10 April 2018
- journal article
- research article
- Published by Wiley in IUBMB Life
- Vol. 70 (5) , 432-436
Abstract
Multiple sclerosis (MS) is a poorly understood disease mechanistically. MOG35‐55 peptide induced experimental autoimmune encephalomyelitis (EAE) is a broadly used model to study MS. Using this model we have earlier shown that the antioxidant tempol or the small molecule inhibitor of p38 SB203580 can effectively prevent EAE progression. This effect was mediated by means of regulating immune inflammation, signaling by the p38MAPK‐SGK1 pathway, and oxidative stress. However, there is a need to test drugs that can be used in pharmacological intervention of EAE. Given that nordihydroguaiaretic Acid (NDGA) has been shown to possess anti‐oxidant activity and capacity of antagonizing autoimmune inflammation, we tested the effect of NDGA in ameliorating EAE in the current study. NDGA showed significant beneficial effect against EAE with both anti‐inflammation and antioxidant activity. NDGA could weaken the immune inflammation at least partly by inhibiting the oxidant stress‐p38MAPK‐SGK1 pathway representing a target for putative pharmacological intervention. © 2018 IUBMB Life, 70(5):432–436, 2018Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 20 references indexed in Scilit:
- mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivoBreast Cancer Research and Treatment, 2012
- p38α MAP Kinase Controls IL-17 Synthesis in Vogt-Koyanagi-Harada Syndrome and Experimental Autoimmune UveitisInvestigative Ophthalmology & Visual Science, 2010
- Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double‐blind, placebo‐controlled clinical studiesArthritis & Rheumatism, 2009
- The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?Annals of Neurology, 2009
- Regulation of pro-inflammatory responses by lipoxygenases via intracellular reactive oxygen species in vitro and in vivoExperimental & Molecular Medicine, 2008
- Current concepts of the cellular and molecular pathophysiology of multiple sclerosisDevelopmental Neurobiology, 2007
- How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosisAnnals of Neurology, 2006
- Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisJournal of Clinical Investigation, 2006
- Nordihydroguaiaretic acid is a potentin vitroscavenger of peroxynitrite, singlet oxygen, hydroxyl radical, superoxide anion and hypochlorous acid and preventsin vivoozone-induced tyrosine nitration in lungsFree Radical Research, 2006
- The arachidonic acid 5‐lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor α activation of microglia and extends survival of G93A‐SOD1 transgenic miceJournal of Neurochemistry, 2004